Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 4 2020 10 07 274 288 Lucio Henrique Sousa Pinheiro Department of Pharmacy, Laboratory of Hematology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil Louise Trindade Department of Pharmacy, Laboratory of Hematology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil Fernandes de Oliveira Amanda Costa Department of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil Nathanielly de Lima Silva Department of Pharmacy, Laboratory of Hematology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil Alex Freire Sandes Department of Medicine, Hematology Course, Federal University of São Paulo, São Paulo, São Paulo, Brazil Marco Antônio Prado Nunes Department of Medicine, Federal University of Sergipe, Aracaju, Sergipe, Brazil Cristiane Bani Correa Department of Morphology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil Carlos Arthur Cardoso Almeida Nursing and Pharmacy School, Federal University of Alagoas, Maceió, Alagoas, Brazil Geydson Silveira da Cruz Hematologist, University Hospital, Federal University of Sergipe, Aracaju, Sergipe, Brazil Divaldo Pereira de Lyra Júnior Department of Pharmacy, Laboratory of Hematology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil Dulce Marta Shimieguel Department of Pharmacy, Laboratory of Hematology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil 2019 10 14 2020 03 01 Background: The aim of this review was to evaluate the influence of aberrant phenotypes in prognosis and survival in acute myeloid leukemia (AML) patients by multiparametric flow cytometry. Materials and Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a review of PubMed, Scopus, Science Direct and Web of Science was carried out through 1998 to 2016, conducted by two reviewers independently, evaluating titles, abstracts and full-texts of the selected studies. Results: Ten studies were included on this review, in which the aberrant phenotype expression of 17 markers were detected in AML patients. From these, 11 aberrant phenotypes were associated with prognosis, which eight had shown negative impact on prognosis: CD7, CD56, CD15, CD2, CD3, CD90low, CD123high, CD117high, and three others were associated with good prognosis: CD19, CD98high and CD117+/CD15+. Meta-analysis showed that aberrant expression of CD56 as a poor prognostic marker with unfavorable outcomes is implicated in decreased overall survival in AML patients in 28 months (95% CI: 0.62 to 0.92). Conclusion: This was observed when there was association between CD56 expression and other prognostic factors, influencing on patients’ management care and treatment. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1194 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1194/869